Mankind Pharma Limited (NSE:MANKIND)

Mankind Pharma Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2024	FY 2023	FY 2023
Period Ending	Mar 31, 2025	Dec 31, 2024	Mar 31, 2024	Dec 31, 2023	Mar 31, 2023
Cash & Equivalents	5,545	5,545	3,820	7,081	3,048
Short-Term Investments	16,908	16,908	7,464	22,581	1,413
Trading Asset Securities	-	-	22,581	-	10,755
Cash & Short-Term Investments	22,453	22,453	33,865	29,662	15,216
Cash Growth	-	-33.70%	14.17%	94.94%	18.94%
Accounts Receivable	15,383	15,383	8,483	8,483	5,764
Other Receivables	-	-	438.13	-	321.02
Receivables	15,423	15,423	8,950	8,511	6,102
Inventory	20,937	20,937	15,535	15,535	14,985
Prepaid Expenses	-	-	603.9	-	331.6
Other Current Assets	11,069	11,069	6,729	11,974	6,645
Total Current Assets	69,883	69,883	65,682	65,682	43,279
Property, Plant & Equipment	32,140	32,140	31,387	31,387	30,170
Long-Term Investments	3,511	3,511	3,111	3,098	3,578
Goodwill	64,926	64,926	200.23	200.2	200.23
Other Intangible Assets	101,236	101,236	16,630	16,630	17,584
Long-Term Deferred Tax Assets	1,079	1,079	803.98	803.9	297.77
Other Long-Term Assets	4,821	4,821	1,818	1,831	2,046
Total Assets	277,595	277,595	119,633	119,633	97,154
Accounts Payable	11,334	11,334	11,030	7,771	10,082
Accrued Expenses	-	-	2,228	-	1,710
Short-Term Debt	-	-	1,515	-	1,150
Current Portion of Long-Term Debt	29,568	29,568	196.96	1,712	244.68
Current Portion of Leases	143.9	143.9	34.23	34.2	25.57
Current Income Taxes Payable	180.8	180.8	463.79	83.8	462.56
Current Unearned Revenue	-	-	1,859	-	1,662
Other Current Liabilities	15,409	15,409	3,871	11,597	3,294
Total Current Liabilities	56,636	56,636	21,197	21,197	18,631
Long-Term Debt	55,262	55,262	248.68	248.7	231.47
Long-Term Leases	140.3	140.3	77.14	77.1	51.78
Long-Term Unearned Revenue	200	200	229.62	229.6	254.95
Long-Term Deferred Tax Liabilities	18,125	18,125	890.69	890.7	773.12
Total Liabilities	131,914	131,914	23,875	23,875	20,922
Common Stock	412.6	412.6	400.59	400.6	400.59
Additional Paid-In Capital	-	-	421.17	-	421.17
Retained Earnings	-	-	101,566	-	82,499
Comprehensive Income & Other	142,911	142,911	-8,757	93,230	-8,969
Total Common Equity	143,324	143,324	93,631	93,631	74,352
Minority Interest	2,358	2,358	2,127	2,127	1,881
Shareholders' Equity	145,682	145,682	95,758	95,758	76,233
Total Liabilities & Equity	277,595	277,595	119,633	119,633	97,154
Total Debt	85,115	85,115	2,072	2,072	1,704
Net Cash (Debt)	-62,661	-62,661	31,793	27,590	13,512
Net Cash Growth	-	-	15.23%	104.19%	241.51%
Net Cash Per Share	-154.85	-154.85	79.25	68.77	33.73
Filing Date Shares Outstanding	412.52	404.01	400.64	400.61	400.59
Total Common Shares Outstanding	412.52	404.01	400.59	400.61	400.59
Working Capital	13,247	13,247	44,485	44,485	24,647
Book Value Per Share	347.44	354.75	233.73	233.72	185.61
Tangible Book Value	-22,838	-22,838	76,800	76,800	56,568
Tangible Book Value Per Share	-55.36	-56.53	191.72	191.71	141.21
Land	-	-	3,530	-	3,528
Buildings	-	-	12,487	-	10,460
Machinery	-	-	21,504	-	17,352
Construction In Progress	-	-	2,071	-	4,932
Leasehold Improvements	-	-	88.68	-	88.74

Source: S&P Global Market Intelligence. Standard template. Financial Sources.